# Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism

> **NCT00467987** · NA · TERMINATED · sponsor: **University at Buffalo** · enrollment: 47 (actual)

## Conditions studied

- Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism

## Interventions

- **DRUG:** androgel
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00467987
- **Lead sponsor:** University at Buffalo
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-06-01
- **Primary completion:** 2018-03-01
- **Final completion:** 2018-10-11
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** Company no longer making same drug doses.
- **Last updated:** 2024-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00467987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00467987, "Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00467987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*